Table 5. Incidence of ONJ.
| Bisphosphonate exposure (months) | Number of patients | Mean duration of bisphosphonates (months) | Mean duration of TKI use (months) | Incidence ONJ |
|---|---|---|---|---|
| 1–6 | 24 | 2.4 | 5.0 | 1/24 (4%) |
| 7–12 | 10 | 9.7 | 10.8 | 1/10 (10%) |
| 13–24 | 6 | 17.3 | 10.0 | 1/6 (17%) |
| 25–36 | 6 | 30.2 | 32.0 | 1/6 (17%) |
| 37–84 | 6 | 50.8 | 26.0 | 1/6 (17%) |
| Cumulative exposure of bisphosphonates (months) | Number of patients | Mean duration of bisphosphonates (months) | Mean duration of TKI use (months) | Incidence ONJ |
| 1–12 | 34 | 4.6 | 7.0 | 2/34 (6%) |
| 1–24 | 40 | 6.5 | 7.0 | 3/40 (8%) |
| 1–36 | 46 | 9.6 | 10.0 | 4/46 (9%) |
| 1–84 | 52 | 14.3 | 12.3 | 5/52 (10%) |
| >12 | 18 | 32.8 | 23.0 | 3/18 (17%) |
| >24 | 12 | 40.5 | 29.0 | 2/12 (17%) |
Abbreviations: ONJ=osteonecrosis of the jaw; TKI=tyrosine kinase inhibitor.
Note: One patient received bisphosphonates for 84 months.